

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Letermovir for the prophylaxis of cytomegalovirus reactivation or disease in people with seropositive-cytomegalovirus who have had an allogeneic haematopoietic stem cell transplant

Batch 56

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

No equality issues were identified during the scoping process.
--

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

No potential equality consideration were identified for the committee.
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No changes have been made to the scope.

- | | |
|----|--|
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes |
|----|--|

Technology Appraisals: Scoping

Equality impact assessment for the Single Technology Appraisal of letermovir for the prophylaxis of cytomegalovirus reactivation or disease in people with seropositive-cytomegalovirus who have had an allogeneic haematopoietic stem cell transplant

Issue date: January 2018

to the matrix been made?
No addition stakeholders identified during scoping process.

Approved by Associate Director (name): Helen Knight

Date: 09/01/2018